An isothermal GLC determination of the plasma levels of carbamazepine, diphenylhydantoin, phenobarbitone and primidone

1. Phenobarbitone in a dose of 180 mg daily was administered to ten normal subjects for 3 weeks. There was a significant increase in total plasma cholesterol, plasma low-density-lipoprotein cholesterol, plasma low-density-lipoprotein (LDL) triglycerides and plasma LDL protein. The increase in plasma LDL cholesterol accounted for the increase in total plasma cholesterol. There was a significant reduction in the ratio of LDL cholesterol to LDL protein. 2. No significant changes were observed in total plasma triglycerides, plasma very-low-density-lipoprotein (VLDL) triglycerides, plasma VLDL cholesterol or plasma VLDL protein. 3. Evidence that drug-metabolizing enzymes were induced by phenobarbitone was provided by an increase in antipyrine clearance. No relationship was observed between changes in plasma cholesterol and changes in antipyrine clearance. Serum gamma-glutamyl transpeptidase was also increased after phenobarbitone administration, the increase being unrelated to changes in antipyrine clearance or plasma cholesterol.

show abstract

“…Serum phenobarbitone concentrations were measured by gas-liquid chromatography (Toseland, Grove & Berry, 1972).…”

Section: Methodsmentioning

confidence: 99%

Effect of Phenobarbitone on Plasma Lipids in Normal Subjects

et al. 1976

View full text Add to dashboard Cite

show abstract

“…Serum phenytoin, phenobarbitone and primidone were estimated after 2 weeks of active drug and after 2 weeks of placebo treatment. The three drugs were estimated simultaneously by the gas chromatographic method of Toseland, Grove & Berry (1972). This method does not require the formation of a derivative before chromatography.…”

Section: Methodsmentioning

confidence: 99%

Controlled Trial of Frusemide as an Antiepileptic Drug in Focal Epilepsy

Ahmad

Clarke

Hewett³

et al. 1976

Brit J Clinical Pharma

View full text Add to dashboard Cite

The antiepileptic activity of oral frusemide (120 mg daily) was compared with that of an identical placebo in a double-blind crossover trial in fourteen patients with severe focal epilepsy who were receiving long-term therapy with established antiepileptic drugs. 2 A statistically significant reduction in the frequency of focal fits was seen with the active drug. 3 Marked drowsiness occurred in three patients during frusemide therapy, causing their withdrawal from the trial. 4 A slight, but significant, rise in serum phenobarbitone concentrations was observed during frusemide therapy, but no change was seen in serum primidone or phenytoin concentrations. 5Frusemide significantly lowered plasma sodium and potassium concentrations, and increased plasma bicarbonate.

show abstract

“…The animals were then sacrificed at half hour intervals, up to two and a half hours. Blood and brain samples were obtained and analysed for DPH (Toseland et al, 1972) and sodium valproate (Patsalos et al, 1975) concentration.…”

mentioning

confidence: 99%